Table 2.
Efficacy outcomes (intervention period)
| All (n = 228) | Group A (n = 155) |
Group B (n = 73) |
p | |
|---|---|---|---|---|
| Therapeutic success—n (%) | ||||
| Yes | 213 (93.4) | 144 (92.9) | 69 (94.5) | 0.646 |
| No | 15 (6.6) | 11 (7.1) | 4 (5.5) | |
| Number of treatment sessions—Mean ± SD | 1.51 ± 0.74 | 1.43 ± 0.65 | 1.68 ± 0.86 | |
| 1 session—n (%) | 145 (63.6) | 103 (66.5) | 42 (57.5) | 0.013 |
| 2 sessions—n (%) | 50 (21.9) | 38 (24.5) | 12 (16.4) | |
| 3 sessions—n (%) | 33 (14.5) | 14 (9.0) | 19 (26.0) | |
| Polidocanol dosage (total)—Mean ± SD | 22.6 ± 10.9 | 22.5 ± 10.5 | 22.9 ± 11.7 | 0.763 |
| Bleeding grade variation*—Mean ± SD | − 1.54 ± 0.71 | – 1.39 ± 0.70 | − 1.85 ± 0.64 | < 0.001 |
| Sodergren score variation*—Mean ± SD | − 7.31 ± 3.70 | – 7.14 ± 3.70 | − 7.67 ± 3.70 | < 0.001 |
SDstandard deviation
*Variable computed as measurement in the end of the intervention period minus baseline
Tests used to compare variables between groups: T test (Average number of treatment sessions; Polidocanol dosage, Sodergren score variation); Mann–Whitney test (Bleeding grade variation, Goligher grade variation); Chi-square test (Therapeutic success)